首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1736509

全球愛滋病毒疫苗市場規模：按類型、抗生素和地區分類的範圍和預測

Global HIV Vaccines Market Size By Type (Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia), By Antibiotics (Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment), By Geographic Scope And Forecast

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

HIV疫苗市場規模及預測

預計 2024 年愛滋病毒疫苗市場規模將達到 3.5001 億美元，到 2032 年將達到 5.6892 億美元，2026 年至 2032 年的複合年成長率為 6.24%。

疫苗可以增強人體免疫系統，幫助預防疾病和感染。如果免疫系統對愛滋病毒（HIV）沒有反應，它會產生抗體來減緩病毒的生長，但無法阻止其生長。通常，HIV疫苗是使用減毒或去活化病毒製成的。 HIV變異很快，因此，雖然疫苗針對的是某種病毒，但病毒本身的變異會導致疫苗失效。然而，用於治療HIV的抗逆轉錄病毒藥物仍是預防HIV感染的主要目標。全球HIV疫苗市場報告對市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球愛滋病毒疫苗市場

目前，全球約有3,500萬人感染愛滋病毒（HIV），自愛滋病疫情爆發以來，約有3,000萬人死於愛滋病。目前尚無已知的HIV感染後自行康復的病例。 HIV複製速度極快，目前全球存在多種不同類型的HIV，且新型病毒仍在不斷繁殖。許多科學家正在努力了解免疫系統對HIV感染的具體反應。疫苗是最有效且最具成本效益的疾病預防手段之一。能夠預防HIV感染或阻止其發展進程的疫苗將大大有助於對抗HIV。

疫苗在全球根除天花的努力中發揮了至關重要的作用，幾乎根除了脊髓灰質炎，並逐漸降低了全球麻疹和百日咳等感染疾病的發生率。然而，一個問題是，HIV疫苗應該針對單一株開發，還是針對多種株結構設計？其目標是提供更有效的藥物來根除這種病毒。這也引出了一個問題：HIV疫苗如何保護個人？疫苗可能無法預防感染，但可以阻止或減緩疾病的進展。

HIV預防教育和諮詢是任何疫苗計畫的重要組成部分，即使在疫苗發布後，仍需要持續有效的行為抑制計畫。預防性HIV疫苗的成功研發將取決於全球公共和私營部門的參與。目前，沒有任何政府或公司有足夠的資源或勇氣獨自承擔HIV疫苗的舉措。在公共部門，包括衛生、經濟發展和國際發展在內的多個不同機構都需要開發HIV疫苗。

全球愛滋病疫苗市場概況

推動市場成長的主要因素是愛滋病毒感染率的上升。此外，人們對感染疾病的認知不斷提高，也是推動市場成長前景樂觀的因素。此外，為開發最有效的疫苗而持續投入研發活動，也推動了市場的成長。然而，疫苗相關的成本以及頻繁的檢測失敗可能會減緩市場的成長。

市場趨勢包括抗逆轉錄病毒療法長效抑制劑（ATLAS）的開發。 ATLAS 是一種注射藥物，目前正在進入市場，與其他藥物相比，其療效顯著提高。 ATLAS 可作為現有 HIV 治療方案的替代方案。

成長背後的驅動力之一是新產品上市和藥物核准數量的不斷增加。對愛滋病毒治療研發的日益重視，推動了新藥的創新，例如吉利德科學和VIIV Healthcare。此外，許多公司正在全球範圍內建立戰略合作夥伴關係並開發新藥。

限制因素之一是缺乏治療途徑以及對愛滋病毒感染的無知，這可能會阻礙市場成長。儘管研發方面取得了許多進展，科學認知也不斷提高，但許多愛滋病毒感染者仍無法及時獲得治療。目前，這種感染疾病仍然無法治療方法。此外，許多人並不了解自己感染了感染疾病。根據 BioMed Central Ltd. 的一項調查，在 478 名參與企業中，三分之一的人報告為愛滋病毒陰性，這是阻礙市場參與企業成長的因素。

The immune system of the body can be boosted using the vaccine, which serves the protection against disease and infection. When the immune system fails to respond to HIV, it generates antibodies to slow the spread, it doesn't stop. Generally, HIV vaccines are made using weakened or killed viruses. HIV mutates quickly, and the vaccine targets the viruses in one form, the change in the virus results in vaccine failure. However, antiretroviral drugs anticipated for HIV, preventing HIV infection is still a primary goal. The Global HIV Vaccines Market report provides a holistic evaluation of the market. The report thoroughly analyzes important segments, trends, drivers, restraints, competitive landscape, and factors that play a substantial role in the market.

Global HIV Vaccines Market Definition

Worldwide, around 35 million people currently are infected with HIV, about 30 million people died due to AIDS infection since the beginning of the epidemic. There is no human example of clearing HIV infections naturally. HIV makes copies of it very quickly, different types of HIV exist in today's world, new types of viruses continue to rise. Many scientists are trying to understand the specific ways of the immune system which need to respond against HIV infection. Vaccines are among the foremost powerful and cost-effective disease prevention tools. The vaccine that could prevent HIV infection or stop the development of the disease would greatly support the fight against this disease.

Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio, and have gradually reduced the incidence of infectious diseases like measles and pertussis across the world. However, the question arises whether the HIV vaccine should be developed for a single strain or should be designed for varied strain structures. The whole aim is to provide better medication for the eradication of this virus by any means. There are also questions that arise about how an HIV vaccine would protect the individuals and the vaccine might not be able to prevent the infections, but stop or delay progression to diseases, or can simply reduce the infectiousness of people who are infected with HIV.

HIV prevention education and counseling are important factors to be discussed in vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral hindrance programs. The successful development of a preventive HIV vaccine positively depends upon the involvement of both the private and public sectors across the world. Currently, no government or company has the resources and encouragement to take on the initiative of developing an HIV vaccine alone. Within the public sector, the development of the HIV vaccine is necessary for several different agencies, including concerns in health, economic development, and international development.

Global HIV Vaccines Market Overview

The main factor which contributes to fueling the market growth is the growing prevalence of HIV infection. Additionally, the increasing awareness among the population regarding the infection is another factor propelling a positive outlook on the growth of the market. Moreover, the continuous expenditure on research and development activities for the development of the most effective vaccination is driving market growth. However, the expense related to the vaccines and frequent trial failure can decline the market growth.

Some of the trends in the market include the development of antiretroviral therapy as a long-acting suppression (ATLAS) is an injectable formulation that has now entered the market and has increased the standard of care compared to the other drugs. It acts as an alternative option for the existing HIV drugs.

One of the driving factors is the increasing number of new product launches and rising drug approvals to boost growth. The growing emphasis on the research and development of HIV drugs has led to new drug innovations such as Gilead Sciences, VIIV healthcare, and many more. Furthermore, many companies are involved in strategic collaborations and new medications worldwide.

One of the restraining factors is a lack of access to treatment and unawareness of HIV infection which may hinder the growth. Despite many advancements in research and development and improved scientific understanding, many people infected with HIV do not have access to timely treatment. This infection still has no treatment available. Additionally, many people are still unaware of this infection. A study conducted by BioMed Central Ltd. reported that amongst the 478 participants, one-third of the participants were unaware of it, this is the reason which may hinder the growth of the market.

Global HIV Vaccines Market Segmentation Analysis

The Global HIV Vaccines Market is segmented on the basis of Type, Antibiotics, And Geography.

HIV Vaccines Market, By Type

Pyogenic Paronychia
Chronic Paronychia
Candidal Paronychia
Acute Paronychia
Others

Based on Type, The market is bifurcated into Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia, Acute Paronychia, and Others.

HIV Vaccines Market, By Antibiotics

Dicloxacillin
Fusidic Acid Ointment
Gentamicin Ointment
Mupirocin Ointment
Others

Based on Antibiotics, The market is bifurcated into Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, Mupirocin Ointment, and Others.

HIV Vaccines Market, By Geography

North America
Europe
The Asia Pacific
Rest of the world

Based on Regional Analysis, The Global HIV Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Europe is expected to be the largest market during the forecast period. Due to the increase in HIV cases and the presence of a large number of HIV companies in the region. The rising strategic collaborations amongst the European Companies will improve drug availability, which will support the growth of the market.

Key Players

The "Global HIV Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are VIIV healthcare, Gilead Sciences, Inc, GlaxoSmithKline plc, Merck Sharp & Dohme Corp., AbbVie Inc, Mylan N.V, and many more. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally.

Key Developments

March 2021, Gilead Sciences Inc and Merck announced a collaboration agreement to co-develop and commercialize long-acting treatments for HIV. The companies plan to combine Gilead's investigational capsid inhibitor Lenacapavir and Merck's investigational nucleoside reverse translocation inhibitor to develop a two-drug regimen for HIV.
January 2021, VIIV Healthcare received U.S FDA approval for Cabenuva, an injection indicated for the treatment of human immunodeficiency virus type 1 (HIV) for adults.

1 INTRODUCTION OF GLOBAL HIV VACCINES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HIV VACCINES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL HIV VACCINES MARKET, BY TYPE

5.1 Overview
5.2 Pyogenic Paronychia
5.3 Chronic Paronychia
5.4 Candidal Paronychia
5.5 Acute Paronychia
5.6 Others

6 GLOBAL HIV VACCINES MARKET, BY ANTIBIOTICS

6.1 Overview
6.2 Dicloxacillin
6.3 Fusidic Acid Ointment
6.4 Gentamicin Ointment
6.5 Mupirocin Ointment
6.6 Others

7 GLOBAL HIV VACCINES MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL HIV VACCINES MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 VIIV healthcare
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Antigen Express
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Gilead Sciences, Inc
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 GlaxoSmithKline plc
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Merck Sharp & Dohme Corp.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 AbbVie Inc
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Mylan N.V
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments